You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 28, 2024

Details for Patent: 8,653,260

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,653,260 protect, and when does it expire?

Patent 8,653,260 protects GEMTESA and is included in one NDA.

This patent has fifty-five patent family members in forty countries.

Summary for Patent: 8,653,260

Title:	Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Abstract:	The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of .beta.3-adrenoceptor. ##STR00001##
Inventor(s):	Berger; Richard (Princeton, NJ), Chang; Lehua (Ramsey, NJ), Edmondson; Scott D. (Clark, NJ), Goble; Stephen D. (Edison, NJ), Ha; Sookhee Nicole (Warren, NJ), Kar; Nam Fung (Brooklyn, NY), Kopka; Ihor E. (Hampton, NJ), Li; Bing (Towaco, NJ), Morriello; Gregori J. (Randolph, NJ), Moyes; Chris R. (Westfield, NJ), Shen; Ding-Ming (Edison, NJ), Wang; Liping (Dayton, NJ), Zhu; Cheng (Edison, NJ)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	13/527,934
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 8,653,260

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Urovant	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial		Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,653,260

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072043	⤷ Try a Trial
Austria	E535521	⤷ Try a Trial
Australia	2009231714	⤷ Try a Trial
Brazil	PI0909768	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.